Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 12:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 866 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Switch Clear all
Completed Not applicable Interventional

Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes

NCT06865989
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Type 2
Interventions
Omnipod 5 SmartAdjust 2.0 System, Omnipod 5 System
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
2 Years to 70 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
11
States / cities
Los Angeles, California • Santa Barbara, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 18, 2026, 12:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assess Biomarkers of Tobacco Exposure and Nicotine Pharmacokinetics in Smokers After a 5-Day In-Clinic Confinement Switch to an Electronic Cigarette or Nicotine Gum

NCT02323438
View directory record Official record
Conditions
Smoking
Interventions
Usual Brand Cigarette, Electronic Cigarette #1, Electronic Cigarette #2, Leading U.S. Nicotine Gum
Other
Lead sponsor
R.J. Reynolds Vapor Company
Industry
Eligibility
21 Years to 60 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 18, 2026, 12:28 AM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

NCT01730040
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
56
States / cities
Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 18, 2026, 12:28 AM EDT
Completed Not applicable Interventional Results available

A Digital Intervention to Improve Physical Activity and Sleep Behaviors in Youth With Psychiatric Diagnoses

NCT05505578
View directory record Official record
Conditions
Psychiatric Diagnosis
Interventions
GamerFit Condition, Comparator Condition
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
13 Years to 17 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Baton Rouge, Louisiana • North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 18, 2026, 12:28 AM EDT
Completed Phase 2 Interventional Results available

Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection

NCT00739934
View directory record Official record
Conditions
Candidiasis, Candidemia
Interventions
voriconazole (Vfend)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 11 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Tucson, Arizona • Orange, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2011 · Synced Oct 18, 2026, 12:28 AM EDT
Recruiting Phase 2 Interventional

Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

NCT06790602
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (mPDAC)
Interventions
Cemiplimab Plus Gemcitabine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 18, 2026, 12:28 AM EDT
Completed Not applicable Interventional Results available

Sleep, Hypertension, and Nocturia: a Multicomponent Approach for Comorbid Illnesses

NCT05419830
View directory record Official record
Conditions
Nocturia, Hypertension, Sleep Disturbance
Interventions
BBTI, PM antihypertensive dosing or Chronotherapy, AM antihypertensive dosing
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 18, 2026, 12:28 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT06747351
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
TAK-881, HYQVIA, SC Investigational Needle Sets
Biological · Device
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
16
States / cities
Scottsdale, Arizona • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 18, 2026, 12:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Testing the Impact of Two Posters on Contraceptive Knowledge, Contraceptive Preferences, and Perceived Pregnancy Risk

NCT03372369
View directory record Official record
Conditions
Contraception, Knowledge, Attitudes, Practice
Interventions
View CDC Poster, View Patient-Centered Poster
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
990 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 18, 2026, 12:28 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Switching to Very Low Nicotine Content Cigarettes vs Reducing Cigarettes Per Day

NCT03060083
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Very low nicotine content (VLNC) cigarettes and nicotine replacement therapy (NRT), Reduce cigarettes per day (CPD) with nicotine replacement therapy (NRT)
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 18, 2026, 12:28 AM EDT
Terminated Phase 4 Interventional Results available

Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors

NCT06162663
View directory record Official record
Conditions
Breast Cancer, Insomnia
Interventions
Suvorexant Tablets, Placebo Control
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 18, 2026, 12:28 AM EDT
Terminated Phase 2 Interventional Results available

Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

NCT04564339
View directory record Official record
Conditions
Lupus Nephritis, Immunoglobulin A Nephropathy
Interventions
Ravulizumab, Placebo, Background Therapy
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
17
States / cities
San Dimas, California • Santa Monica, California • South Gate, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 18, 2026, 12:28 AM EDT
Completed Phase 2 Interventional Results available

Double-Blind Treatment of Major Depressive Disorder With Vilazodone

NCT01742832
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone, Citalopram
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 60 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 18, 2026, 12:28 AM EDT
Completed Phase 4 Interventional Results available

Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes

NCT00338949
View directory record Official record
Conditions
Schizophrenia, Metabolic Syndrome X, Insulin Resistance
Interventions
Switch, Control
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 18, 2026, 12:28 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

NCT06630299
View directory record Official record
Conditions
HIV-1-Infection
Interventions
ISL/LEN, Antiretroviral Combinations
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 18, 2026, 12:28 AM EDT
Terminated Phase 2 Interventional Results available

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

NCT03809663
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tezepelumab, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Fountain Valley, California • Santa Monica, California • Alpharetta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 18, 2026, 12:28 AM EDT
Recruiting Phase 4 Interventional

Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

NCT06964464
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF), Sudden Cardiac Death, Ventricular Arrhythmia, Implantable Cardioverter Defibrillator (ICD), Beta-blocker Therapy, Cardiomyopathy
Interventions
Metoprolol Succinate, Carvedilol
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
13
States / cities
Scottsdale, Arizona • Rome, Georgia • Shawnee Mission, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 18, 2026, 12:28 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)

NCT03251144
View directory record Official record
Conditions
HIV/AIDS, Antiviral Toxicity, Antiviral Drug Adverse Reaction, Mitochondrial Alteration
Interventions
Switch to E/C/FTC/TAF daily
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 18, 2026, 12:28 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

NCT01977482
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, Placebo, rhEPO
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Azusa, California • Los Angeles, California • San Dimas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 18, 2026, 12:28 AM EDT
Completed No phase listed Observational

Children's Exposures/Health Effects/Diesel Exhaust

NCT00527345
View directory record Official record
Conditions
Asthma, Airway Inflammation
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
6 Years to 11 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 18, 2026, 12:28 AM EDT
Terminated Not applicable Interventional

Efficacy Rate of Unipolar Polarity Switch for Lesion Assessment in Pulmonary Vein Isolation

NCT05464537
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Unipolar Polarity Switch Left, Unipolar Polarity Switch Right
Other
Lead sponsor
Kansas City Heart Rhythm Research Foundation
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 18, 2026, 12:28 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders

NCT01624142
View directory record Official record
Conditions
Severe Familial Hypercholesterolemia
Interventions
Evolocumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
6
States / cities
Los Angeles, California • New York, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 18, 2026, 12:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Smoking Environments on Craving and Smoking (CameraCue2.0)

NCT02551692
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Nicotine Patch, Varenicline, Placebo Nicotine Patch, Placebo Capsule
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 18, 2026, 12:28 AM EDT
Recruiting Not applicable Interventional

Harm Reduction for Smokers With Mental Illness

NCT06543407
View directory record Official record
Conditions
Tobacco Dependence
Interventions
SWITCH IT, E-cig Provision Only
Behavioral · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Louisville, Kentucky • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 18, 2026, 12:28 AM EDT